Insurance Denied Rare Disease Treatment — Orphan Drug and Compassionate Use Appeals

Living with a rare disease means navigating a healthcare system that was not designed for you. You may have waited years for a diagnosis. Your condition may have fewer than a thousand patients in the entire country. And when an approved treatment — or an experimental one that could change your life — is denied by your insurance company, it can feel like a wall with no door. There are doors. This guide shows you where to find them.

Why Rare Disease Treatment Is Denied

Rare disease treatment denials have several distinct characteristics compared to common condition denials:

• High cost: Many orphan drugs cost $100,000–$500,000+ per year. Insurers push back based on cost in ways they might not for cheaper drugs, using medical necessity as the justification.
• "Experimental" classification: Treatments approved under the FDA's accelerated approval pathway or approved based on surrogate endpoints may be classified as experimental by insurers despite FDA approval.
• Off-label use: The only available treatment may be a drug approved for a different (often more common) condition, used off-label for your rare disease.
• No established clinical criteria: For very rare conditions, published clinical guidelines and insurer coverage policies may not exist — leaving patients in a policy vacuum.
• Formulary exclusion: Orphan drugs are often not on standard formularies, requiring non-formulary exception requests.
• Compassionate use / expanded access denied: Experimental treatments accessed outside clinical trials are denied as non-covered investigational care.

Federal Protections for Rare Disease Patients

The Orphan Drug Act provides incentives for drug development for rare diseases (affecting fewer than 200,000 people in the US) but does not directly mandate insurance coverage. However, once an orphan drug has FDA approval, it is no longer "experimental" — and denials based on experimental status must be challenged on that basis.

The ACA's prohibition on lifetime and annual limits is particularly important for rare disease patients, who may require treatment for decades at high cost. Plans cannot impose dollar limits on essential health benefits.

The ACA's External Independent Review: Complete Guide" class="auto-link">external review provisions are also critical — external reviewers applying clinical standards (rather than cost-focused insurer criteria) are an important remedy for rare disease coverage disputes.

Building a Rare Disease Appeal

Appeals for rare conditions require extra documentation because standard criteria may not exist:

1. Specialist physician letter — from a physician who specializes in or has expertise in your condition. For rare diseases, this may be a specialist at a major academic medical center. Their letter carries significant weight precisely because of their expertise.
2. FDA approval documentation — if the drug has FDA approval (even under accelerated approval), document this explicitly with the approval letter or drug label.
3. Published literature — even small-scale studies, case series, or disease registry data are relevant when guideline-level evidence does not exist.
4. Patient registry data — many rare disease organizations maintain patient registries documenting treatment outcomes that can be cited.
5. No alternative treatment argument — if your denied treatment is the only available option for your condition, document that explicitly. There is no step therapy when there is no approved step.
6. Orphan disease designation documentation — FDA's Office of Orphan Products Development designation can support the argument that your treatment represents the standard of care for your condition.

Compassionate Use and Expanded Access

If you are seeking access to an investigational drug outside a clinical trial, the FDA's Expanded Access (Compassionate Use) Program may be an option. The FDA approves expanded access for individual patients when:

• There is a serious or life-threatening condition
• No comparable treatment alternatives exist
• Potential benefits outweigh risks

If your insurer denies coverage of an expanded access treatment, the appeal must document the FDA's authorization of expanded access as evidence that this treatment is not simply "experimental" — it is a recognized pathway for patients with no other options.

When Insurer Coverage Criteria Do Not Exist

For very rare conditions where the insurer has no written coverage policy, they cannot default to denial. Under ACA rules, the absence of a coverage policy does not equal non-coverage for medically necessary care. Your appeal should include:

• Your specialist's letter establishing the medical necessity standard for your specific condition
• Published disease-specific literature establishing the requested treatment as appropriate
• A request for the insurer to explain the clinical basis for their denial when no formal policy exists

Disease-Specific Advocacy Organizations

The rare disease community has some of the most robust patient advocacy organizations in medicine. Find yours:

• National Organization for Rare Disorders (NORD) (rarediseases.org) — comprehensive database of rare diseases and patient assistance programs
• Global Genes (globalgenes.org) — advocacy and support for rare disease patients
• EveryLife Foundation for Rare Diseases (everylifefoundation.org) — policy advocacy
• Your disease-specific foundation — organizations for conditions like Gaucher disease, PKU, lysosomal storage disorders, muscular dystrophies, and hundreds of others often have insurance navigation experts on staff

Fight Back With ClaimBack

You deserve access to the treatment that exists for your condition, no matter how rare it is. ClaimBack helps rare disease patients build evidence-based, specialist-supported appeals that challenge insurer denials with the clinical and regulatory arguments that matter.

Start your appeal at https://claimback.app/appeal.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal — Know the Difference